Management of Non-Sustained Ventricular Tachycardia with Amiodarone

Assessment and Treatment

The American Heart Association recommends that amiodarone is an appropriate treatment for symptomatic non-sustained ventricular tachycardia (NSVT), particularly when it causes hemodynamic compromise, but should not be used routinely for asymptomatic NSVT 1, 2
NSVT (defined as 3 or more consecutive ventricular beats at a rate >100 beats/minute lasting <30 seconds) is common in patients with heart disease but its prognostic significance varies based on underlying cardiac condition 1
A 20-beat run of NSVT is relatively long and warrants careful evaluation for underlying structural heart disease, particularly if symptomatic 3, 2
Asymptomatic NSVT generally does not require specific antiarrhythmic therapy, as suppression of NSVT with antiarrhythmic drugs has not been shown to improve survival 1, 4

Amiodarone should not be considered part of routine treatment for patients with asymptomatic NSVT 1, 5
For hemodynamically relevant NSVT, amiodarone (300 mg IV bolus) should be considered 2
Amiodarone remains the agent most likely to be safe and effective when antiarrhythmic therapy is necessary for symptomatic ventricular arrhythmias 1, 5
Unlike other antiarrhythmic drugs, amiodarone has been associated with neutral effects on survival in patients with reduced ejection fraction 1

Beta-blockers should be considered as first-line therapy for prevention of ventricular arrhythmias before considering amiodarone 3, 2
If NSVT is associated with acute coronary syndrome, consider coronary angiography as recurrent arrhythmias may indicate incomplete revascularization 2
For recurrent symptomatic NSVT despite medical therapy, catheter ablation may be effective, especially if triggered by premature ventricular complexes from injured Purkinje fibers 3, 2
Consider evaluation for ICD therapy in patients with NSVT who have significant structural heart disease, particularly those with reduced ejection fraction (≤35%) 1, 4

Amiodarone may act through mechanisms other than pure antiarrhythmic effects, as it has been shown to increase left ventricular ejection fraction and decrease the incidence of worsening heart failure in some trials 1

Do not use prophylactic antiarrhythmic drugs for asymptomatic NSVT as they have not proven beneficial and may be harmful 2, 4
Avoid class IC antiarrhythmic drugs (flecainide, propafenone) in patients with structural heart disease or prior myocardial infarction due to increased mortality risk 1, 6

Hemodynamic compromise due to bigeminy should prompt consideration of intervention, according to the European Society of Cardiology 7
Monitoring for amiodarone-related bradycardia is crucial, as it can be more common in women and may require pacemaker implantation, as recommended by the American Heart Association 8
Assessment of QT interval on ECG is necessary, as amiodarone can prolong QT and increase proarrhythmic risk, as noted by the American Heart Association 8
If recurrent non-sustained VTach returns, ruling out ischemia with urgent angiography if indicated is essential, as suggested by the European Society of Cardiology 7
Consideration of transvenous catheter pace termination for frequently recurrent episodes is recommended, according to the European Society of Cardiology 7
Evaluation for ICD therapy if structural heart disease with reduced ejection fraction is present is necessary, although the specific guideline society is not mentioned in the provided reference 7
Avoid using calcium channel blockers to treat wide-complex rhythms of unknown origin, as advised by the European Society of Cardiology 7
Electrophysiology study to guide further therapy should be considered if the patient develops new sustained VTach, hemodynamic instability, or symptomatic arrhythmias despite amiodarone, as recommended by the European Society of Cardiology 7